Wouter A van der Linden
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.
11.06.2015The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
11.06.2015Haematologica 2015; 100:1350-60
Kraus Marianne, Overkleeft Herman, Kisselev Alexei F, Li Nan, Appenzeller Christina, van Rooden Eva, Haile Sarah, de Bruin Gerjan, van der Linden Wouter A, Shabaneh Tamer B, Silzle Tobias, Mirabella Anne C, Weyburne Emily S, Geurink Paul P, Bader Juergen, Driessen Christoph
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites
Geurink P, Overkleeft H, Groll M, van der Stelt M, Driessen C, van der Marel G, Florea B, Mock E, Voges M, Blom A, de Bruin G, Gallastegui N, Mirabella A, van der Linden W, Kisselev A. Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem 2013; 56:1262-75.
28.01.2013Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites
28.01.2013J Med Chem 2013; 56:1262-75
Geurink Paul P, Overkleeft Herman S, Groll Michael, van der Stelt Mario, Driessen Christoph, van der Marel Gijs A, Florea Bogdan I, Mock Elliot D, Voges Mathias J, Blom Annet E M, de Bruin Gerjan, Gallastegui Nerea, Mirabella Anne C, van der Linden Wouter A, Kisselev Alexei F